Catalent has been the main supplier of fill-finish and packaging services for Novo Nordisk’s Glucagon-like peptide-1 (GLP-1) syringes and injection pens, and the deal will see the sale of Catalent’s fill-finish sites in Italy, Belgium and Bloomington in the U.S. sold to Novo Nordisk, expanding its in-house manufacturing capabilities of weight loss and obesity-targeting drugs.

IGC Pharma is progressing towards a Phase 1 clinical trial for its proprietary Alzheimer's drug candidate, IGC-AD1, after demonstrating promising preclinical results.

French clinical-stage biotechnology company Vivet Therapeutics has been granted $5.3 million through the France Health Innovation Plan 2030 to support the company's pioneering work in gene therapy.

Global pharmaceutical company, Teva Pharmaceutical, has announced plans to divest its API business, aligning with its 'Pivot to Growth' strategy. This move aims to reduce complexity and enhance profitability, whilst enabling them to focus on streamlining operations and focusing on core capabilities in generics, specialty medicines, and biopharmaceuticals.

Upperton Pharma Solutions announced a significant expansion into sterile drug manufacturing with the launch of a new c. $6.3 million GMP facility.

Bora’s Board of Directors approved the acquisition of Upsher-Smith from shareholders Sawai Group Holdings Co., Ltd. (JP), and Sumitomo Corporation of Americas.

Sanner, the healthcare packaging manufacturer and medical device CDMO has acquired Springboard, a specialist medical device designer and developer.

The Sanner Group announced the completion of the structural phase of its new headquarters and development and production site in Bensheim, Germany. The company will go on to fit out the site, and said it expects it will work closely with customers to move all production into the new facility by the beginning of 2025.